Your browser doesn't support javascript.
loading
Molecular Imaging of Diffuse Cardiac Fibrosis with a Radiotracer That Targets Proteolyzed Collagen IV.
Niego, Be'eri; Jupp, Bianca; Zia, Nicholas A; Xu, Rong; Jap, Edwina; Ezeani, Martin; Noor, Asif; Donnelly, Paul S; Hagemeyer, Christoph E; Alt, Karen.
Afiliación
  • Niego B; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Jupp B; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Zia NA; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Xu R; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Jap E; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Ezeani M; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Noor A; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Donnelly PS; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Hagemeyer CE; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
  • Alt K; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Mel
Radiol Cardiothorac Imaging ; 6(2): e230098, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38512024
ABSTRACT
Purpose To develop an approach for in vivo detection of interstitial cardiac fibrosis using PET with a peptide tracer targeting proteolyzed collagen IV (T-peptide). Materials and Methods T-peptide was conjugated to the copper chelator MeCOSar (chemical name, 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid) and radiolabeled with copper 64 (64Cu). PET/CT scans were acquired following intravenous delivery of 64Cu-T-peptide-MeCOSar (0.25 mg/kg; 18 MBq ± 2.7 [SD]) to male transgenic mice overexpressing ß2-adrenergic receptors with intermediate (7 months of age; n = 4 per group) to severe (10 months of age; n = 11 per group) cardiac fibrosis and their wild-type controls. PET scans were also performed following coadministration of the radiolabeled probe with nonlabeled T-peptide in excess to confirm binding specificity. PET data were analyzed by t tests for static scans and analysis of variance tests (one- or two-way) for dynamic scans. Results PET/CT scans revealed significantly elevated (2.24-4.26-fold; P < .05) 64Cu-T-peptide-MeCOSar binding in the fibrotic hearts of aged transgenic ß2-adrenergic receptor mice across the entire 45-minute acquisition period compared with healthy controls. The cardiac tracer accumulation and presence of diffuse cardiac fibrosis in older animals were confirmed by gamma counting (P < .05) and histologic evaluation, respectively. Coadministration of a nonradiolabeled probe in excess abolished the elevated radiotracer binding in the aged transgenic hearts. Importantly, PET tracer accumulation was also detected in younger (7 months of age) transgenic mice with intermediate cardiac fibrosis, although this was only apparent from 20 minutes following injection (1.6-2.2-fold binding increase; P < .05). Conclusion The T-peptide PET tracer targeting proteolyzed collagen IV provided a sensitive and specific approach of detecting diffuse cardiac fibrosis at varying degrees of severity in a transgenic mouse model. Keywords Diffuse Cardiac Fibrosis, Molecular Peptide Probe, Molecular Imaging, PET/CT © RSNA, 2024.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cobre / Tomografía Computarizada por Tomografía de Emisión de Positrones Límite: Animals Idioma: En Revista: Radiol Cardiothorac Imaging Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cobre / Tomografía Computarizada por Tomografía de Emisión de Positrones Límite: Animals Idioma: En Revista: Radiol Cardiothorac Imaging Año: 2024 Tipo del documento: Article